{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:05:08Z","timestamp":1790715908229,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Fluid biomarkers play important roles in many aspects of neurodegenerative diseases, such as Huntington\u2019s disease (HD). However, a main question relates to how well levels of biomarkers measured in CSF are correlated with those measured in peripheral fluids, such as blood or saliva. In this study, we quantified levels of four neurodegenerative disease-related proteins, neurofilament light (NfL), total tau (t-tau), glial fibrillary acidic protein (GFAP) and YKL-40 in matched CSF, plasma and saliva samples from Huntingtin (<jats:italic>HTT<\/jats:italic>) gene-positive individuals (<jats:italic>n<\/jats:italic>\u2009=\u200921) using electrochemiluminescence assays. In addition, salivary levels of NfL, t-tau, and GFAP were quantified from a larger cohort (<jats:italic>n<\/jats:italic>\u2009=\u200995). We found both positive and negative correlations in the levels of these biomarkers among different biofluids. Most notably, in contrast to the significant positive correlations observed between CSF and plasma levels for NfL and GFAP, we detected significant negative correlations between the CSF and saliva levels of NfL and GFAP. With regard to clinical measures, both plasma and CSF levels of NfL were significantly positively correlated with Total Motor Score and chorea, whereas saliva levels of NfL showed significant correlations in the opposite direction. Additional correlations between salivary biomarkers with clinical data, adjusting for age, sex and CAG repeat length, confirmed that salivary NfL was significantly negatively associated with chorea scores in manifest HD, but not premanifest (PM), individuals. In contrast, salivary t-tau was positively associated with measures of cognition in PM participants. These findings suggest that salivary levels of NfL and t-tau proteins may exemplify non-invasive biomarkers for disease symptoms at different stages of illness. Further, these findings highlight the notion that different forms of disease proteins exist in different biological fluids.<\/jats:p>","DOI":"10.1007\/s00415-024-12785-4","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T16:03:38Z","timestamp":1737648218000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparisons of neurodegenerative disease biomarkers across different biological fluids from patients with Huntington\u2019s disease"],"prefix":"10.1007","volume":"272","author":[{"given":"Alison R.","family":"Bamford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia M.","family":"Parkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jody","family":"Corey-Bloom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2024-4710","authenticated-orcid":false,"given":"Elizabeth A.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"issue":"6","key":"12785_CR1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"Huntington Disease Collaborative Research Group D","year":"1993","unstructured":"Huntington Disease Collaborative Research Group D (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. The Huntington\u2019s disease collaborative research group. Cell 72(6):971\u2013983","journal-title":"Cell"},{"issue":"10","key":"12785_CR2","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1073\/pnas.0308679101","volume":"101","author":"NS Wexler","year":"2004","unstructured":"Wexler NS (2004) Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington\u2019s disease age of onset. Proc Natl Acad Sci USA 101(10):3498\u20133503","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"12785_CR3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1469-1809.2006.00335.x","volume":"71","author":"JM Andresen","year":"2007","unstructured":"Andresen JM, Gay\u00e1n J, Djouss\u00e9 L, Roberts S, Brocklebank D, Cherny SS, US\u2010Venezuela Collaborative Research Group HD MAPS, Collaborative Research Group et al (2007) The relationship between CAG repeat length and age of onset differs for Huntington\u2019s disease patients with juvenile onset or adult onset. Ann Hum Genet 71(3):295\u2013301","journal-title":"Ann Hum Genet"},{"issue":"4","key":"12785_CR4","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/ng0893-398","volume":"4","author":"SE Andrew","year":"1993","unstructured":"Andrew SE, Goldberg YP, Kremer B, Telenius H, Theilmann J, Adam S, Starr E, Squitieri F et al (1993) The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington\u2019s disease. Nat Genet 4(4):398\u2013403","journal-title":"Nat Genet"},{"issue":"1","key":"12785_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.expneurol.2011.12.013","volume":"238","author":"M Arrasate","year":"2012","unstructured":"Arrasate M, Finkbeiner S (2012) Protein aggregates in Huntington\u2019s disease. Exp Neurol 238(1):1\u201311","journal-title":"Exp Neurol"},{"issue":"4","key":"12785_CR6","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","volume":"30","author":"NR Barth\u00e9lemy","year":"2024","unstructured":"Barth\u00e9lemy NR, Salvad\u00f3 G, Schindler SE, He Y, Janelidze S, Collij LE, Saef B, Henson RL et al (2024) Highly accurate blood test for Alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests. Nat Med 30(4):1085\u20131095","journal-title":"Nat Med"},{"issue":"5","key":"12785_CR7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0003-9969(00)00008-X","volume":"45","author":"M Lenander-Lumikari","year":"2000","unstructured":"Lenander-Lumikari M, Ihalin R, Lahteenoja H (2000) Changes in whole saliva in patients with coeliac disease. Arch Oral Biol 45(5):347\u2013354","journal-title":"Arch Oral Biol"},{"issue":"5","key":"12785_CR8","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1080\/00016350510020043","volume":"63","author":"LM Helenius","year":"2005","unstructured":"Helenius LM, Meurman JH, Helenius I, Kari K, Hietanen J, Suuronen R, Hallikainen D, Kautiainen H et al (2005) Oral and salivary parameters in patients with rheumatic diseases. Acta Odontol Scand 63(5):284\u2013293","journal-title":"Acta Odontol Scand"},{"issue":"4","key":"12785_CR9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/jmv.1890300403","volume":"30","author":"P Holmstrom","year":"1990","unstructured":"Holmstrom P, Syrjanen S, Laine P, Valle SL, Suni J (1990) HIV antibodies in whole saliva detected by ELISA and western blot assays. J Med Virol 30(4):245\u2013248","journal-title":"J Med Virol"},{"issue":"5","key":"12785_CR10","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-3083.1993.tb02584.x","volume":"38","author":"S Matsuda","year":"1993","unstructured":"Matsuda S, Oka S, Honda M, Takebe Y, Takemori T (1993) Characteristics of IgA antibodies against HIV-1 in sera and saliva from HIV-seropositive individuals in different clinical stages. Scand J Immunol 38(5):428\u2013434","journal-title":"Scand J Immunol"},{"issue":"1","key":"12785_CR11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1365-263X.1998.00057.x","volume":"8","author":"MA Belazi","year":"1998","unstructured":"Belazi MA, Galli-Tsinopoulou A, Drakoulakos D, Fleva A, Papanayiotou PH (1998) Salivary alterations in insulin-dependent diabetes mellitus. Int J Paediatr Dent 8(1):29\u201333","journal-title":"Int J Paediatr Dent"},{"issue":"1","key":"12785_CR12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1590\/S0103-64402003000100005","volume":"14","author":"ME Lopez","year":"2003","unstructured":"Lopez ME, Colloca ME, Paez RG, Schallmach JN, Koss MA, Chervonagura A (2003) Salivary characteristics of diabetic children. Braz Dent J 14(1):26\u201331","journal-title":"Braz Dent J"},{"issue":"1","key":"12785_CR13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/154407370501800105","volume":"18","author":"C Streckfus","year":"2005","unstructured":"Streckfus C, Bigler L (2005) The use of soluble, salivary c-erbB-2 for the detection and post-operative follow-up of breast cancer in women: the results of a five-year translational research study. Adv Dent Res 18(1):17\u201324","journal-title":"Adv Dent Res"},{"issue":"12","key":"12785_CR14","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","volume":"78","author":"AL Benedet","year":"2021","unstructured":"Benedet AL, Mil\u00e0-Alom\u00e0 M, Vrillon A, Ashton NJ, Pascoal TA, Lussier F, Karikari TK, Hourregue C et al (2021) Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol 78(12):1471\u20131483","journal-title":"JAMA Neurol"},{"key":"12785_CR15","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2023.106356","volume":"189","author":"AL Wojda\u0142a","year":"2023","unstructured":"Wojda\u0142a AL, Bellomo G, Gaetani L, Toja A, Chipi E, Shan D, Chiasserini D, Parnetti L (2023) Trajectories of CSF and plasma biomarkers across Alzheimer\u2019s disease continuum: disease staging by NF-L, p-tau181, and GFAP. Neurobiol Dis 189:106356","journal-title":"Neurobiol Dis"},{"issue":"2","key":"12785_CR16","first-page":"136","volume":"11","author":"K Kieburtz","year":"2001","unstructured":"Kieburtz K, Penney JB, Corno P, Ranen N, Shoulson I, Feigin A, Abwender D, Greenarnyre JT et al (2001) Unified Huntington\u2019s disease rating scale: reliability and consistency. Neurology 11(2):136\u2013142","journal-title":"Neurology"},{"issue":"3","key":"12785_CR17","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR (1975) \u201cMini-mental state\u201d: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189\u2013198","journal-title":"J Psychiatr Res"},{"issue":"4","key":"12785_CR18","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, B\u00e9dirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H (2005) The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53(4):695\u2013699","journal-title":"J Am Geriatr Soc"},{"key":"12785_CR19","volume-title":"A compendium of neuropsychological tests","author":"A Smith","year":"1982","unstructured":"Smith A (1982) Symbol digit modalities test. In: Spreen O, Strauss E (eds) A compendium of neuropsychological tests. Western Psychological Services, Los Angeles"},{"issue":"4","key":"12785_CR20","first-page":"219","volume":"14","author":"D Craufurd","year":"2001","unstructured":"Craufurd D, Thompson JC, Snowden JS (2001) Behavioral changes in Huntington disease. Cogn Behav Neurol 14(4):219\u2013226","journal-title":"Cogn Behav Neurol"},{"issue":"4","key":"12785_CR21","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.adolescence.2012.01.005","volume":"35","author":"DA Granger","year":"2012","unstructured":"Granger DA, Fortunato CK, Beltzer EK, Virag M, Bright MA, Out D (2012) Focus on methodology: salivary bioscience and research on adolescence: an integrated perspective. J Adolesc 35(4):1081\u20131095","journal-title":"J Adolesc"},{"key":"12785_CR22","volume-title":"Practical nonparametric statistics","author":"WJ Conover","year":"1980","unstructured":"Conover WJ (1980) Practical nonparametric statistics. John Wiley and Sons Inc, New York, NY"},{"key":"12785_CR23","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.parkreldis.2021.04.017","volume":"87","author":"GM Parkin","year":"2021","unstructured":"Parkin GM, Corey-Bloom J, Snell C, Castleton J, Thomas EA (2021) Plasma neurofilament light in Huntington\u2019s disease: a marker for disease onset, but not symptom progression. Parkinsonism Relat Disord 87:32\u201338","journal-title":"Parkinsonism Relat Disord"},{"issue":"17","key":"12785_CR24","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1212\/WNL.0000000000003246","volume":"87","author":"N Mattsson","year":"2016","unstructured":"Mattsson N, Zetterberg H, Janelidze S, Insel PS, Andreasson U, Stomrud E, Palmqvist S, Baker D et al (2016) Plasma tau in Alzheimer disease. Neurology 87(17):1827\u20131835","journal-title":"Neurology"},{"issue":"5","key":"12785_CR25","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1578","volume":"10","author":"T Cruickshank","year":"2020","unstructured":"Cruickshank T, Bartlett D, Govus A, Hannan A, Teo WP, Mason S, Lo J, Ziman M (2020) The relationship between lifestyle and serum neurofilament light protein in Huntington\u2019s disease. Brain Behav 10(5):e01578","journal-title":"Brain Behav"},{"issue":"574","key":"12785_CR26","doi-asserted-by":"crossref","first-page":"eabc2888","DOI":"10.1126\/scitranslmed.abc2888","volume":"12","author":"FB Rodrigues","year":"2020","unstructured":"Rodrigues FB, Byrne LM, Tortelli R, Johnson EB, Wijeratne PA, Arridge M, De Vita E, Ghazaleh N et al (2020) Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington\u2019s disease. Sci Transl Med 12(574):eabc2888","journal-title":"Sci Transl Med"},{"issue":"6","key":"12785_CR27","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S1474-4422(20)30143-5","volume":"19","author":"RI Scahill","year":"2020","unstructured":"Scahill RI, Zeun P, Osborne-Crowley K, Johnson EB, Gregory S, Parker C, Lowe J, Nair A et al (2020) Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington\u2019s disease Young Adult Study (HD-YAS): a cross-sectional analysis. Lancet Neurol 19(6):502\u2013512","journal-title":"Lancet Neurol"},{"issue":"8","key":"12785_CR28","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1474-4422(17)30124-2","volume":"16","author":"LM Byrne","year":"2017","unstructured":"Byrne LM, Rodrigues FB, Blennow K, Durr A, Leavitt BR, Roos RAC, Scahill RI, Tabrizi SJ et al (2017) Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington\u2019s disease: a retrospective cohort analysis. Lancet Neurol 16(8):601\u2013609","journal-title":"Lancet Neurol"},{"issue":"458","key":"12785_CR29","doi-asserted-by":"crossref","first-page":"eaat7108","DOI":"10.1126\/scitranslmed.aat7108","volume":"10","author":"LM Byrne","year":"2018","unstructured":"Byrne LM, Rodrigues FB, Johnson EB, Wijeratne PA, De Vita E, Alexander DC, Palermo G, Czech C et al (2018) Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington\u2019s disease. Sci Transl Med 10(458):eaat7108","journal-title":"Sci Transl Med"},{"issue":"7","key":"12785_CR30","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1093\/brain\/awaa098","volume":"143","author":"AR Gafson","year":"2020","unstructured":"Gafson AR, Barth\u00e9lemy NR, Bomont P, Carare RO, Durham HD, Julien JP, Kuhle J, Leppert D et al (2020) Neurofilaments: neurobiological foundations for biomarker applications. Brain 143(7):1975\u20131998","journal-title":"Brain"},{"issue":"8","key":"12785_CR31","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","volume":"90","author":"L Gaetani","year":"2019","unstructured":"Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H (2019) Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry 90(8):870\u2013881","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"12785_CR32","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","volume":"76","author":"C Bridel","year":"2019","unstructured":"Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE, Alvarez-Cerme\u00f1o JC, Andreasson U, Axelsson M et al (2019) Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol 76(9):1035\u20131048","journal-title":"JAMA Neurol"},{"issue":"1\u20132","key":"12785_CR33","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jns.2005.03.015","volume":"233","author":"A Petzold","year":"2005","unstructured":"Petzold A (2005) Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 233(1\u20132):183\u2013198","journal-title":"J Neurol Sci"},{"issue":"17","key":"12785_CR34","doi-asserted-by":"crossref","first-page":"6904","DOI":"10.18632\/aging.102220","volume":"11","author":"H Hu","year":"2019","unstructured":"Hu H, Chen KL, Ou YN, Cao XP, Chen SD, Cui M, Dong Q, Tan L et al (2019) Neurofilament light chain plasma concentration predicts neurodegeneration and clinical progression in nondemented elderly adults. Aging (Albany NY) 11(17):6904\u20136914","journal-title":"Aging (Albany NY)"},{"issue":"7","key":"12785_CR35","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","volume":"76","author":"N Mattsson","year":"2019","unstructured":"Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K (2019) Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol 76(7):791\u2013799","journal-title":"JAMA Neurol"},{"issue":"8","key":"12785_CR36","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/acn3.325","volume":"3","author":"LH Meeter","year":"2016","unstructured":"Meeter LH, Dopper EG, Jiskoot LC, Sanchez-Valle R, Graff C, Benussi L, Ghidoni R, Pijnenburg YA et al (2016) Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann Clin Transl Neurol 3(8):623\u2013636","journal-title":"Ann Clin Transl Neurol"},{"issue":"15","key":"12785_CR37","doi-asserted-by":"crossref","first-page":"e1390","DOI":"10.1212\/WNL.0000000000006318","volume":"91","author":"P Steinacker","year":"2018","unstructured":"Steinacker P, Anderl-Straub S, Diehl-Schmid J, Semler E, Uttner I, von Arnim CAF, Barthel H, Danek A et al (2018) Serum neurofilament light chain in behavioral variant frontotemporal dementia. Neurology 91(15):e1390\u2013e1401","journal-title":"Neurology"},{"issue":"2","key":"12785_CR38","doi-asserted-by":"crossref","first-page":"fcac045","DOI":"10.1093\/braincomms\/fcac045","volume":"4","author":"MM Budelier","year":"2022","unstructured":"Budelier MM, He Y, Barthelemy NR, Jiang H, Li Y, Park E, Henson RL, Schindler SE et al (2022) A map of neurofilament light chain species in brain and cerebrospinal fluid and alterations in Alzheimer\u2019s disease. Brain Commun 4(2):fcac045","journal-title":"Brain Commun"},{"issue":"1","key":"12785_CR39","volume":"5","author":"FJ Meda","year":"2023","unstructured":"Meda FJ, Knowles K, Swift IJ, Sogorb-Esteve A, Rohrer JD, Dittrich A, Skoog I, Kern S et al (2023) Neurofilament light oligomers in neurodegenerative diseases: quantification by homogeneous immunoassay in cerebrospinal fluid. BMJ Neurol Open 5(1):e000395","journal-title":"BMJ Neurol Open"},{"issue":"4","key":"12785_CR40","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1601-0825.2010.01773.x","volume":"17","author":"N Spielmann","year":"2011","unstructured":"Spielmann N, Wong DT (2011) Saliva: diagnostics and therapeutic perspectives. Oral Dis 17(4):345\u2013354","journal-title":"Oral Dis"},{"issue":"1","key":"12785_CR41","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/s41598-023-28019-y","volume":"13","author":"GM Parkin","year":"2023","unstructured":"Parkin GM, Corey-Bloom J, Snell C, Smith H, Laurenza A, Daldin M, Bresciani A, Thomas EA (2023) Salivary huntingtin protein is uniquely associated with clinical features of Huntington\u2019s disease. Sci Rep 13(1):1034","journal-title":"Sci Rep"},{"issue":"7","key":"12785_CR42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180697","volume":"12","author":"H Yoon","year":"2017","unstructured":"Yoon H, Walters G, Paulsen AR, Scarisbrick IA (2017) Astrocyte heterogeneity across the brain and spinal cord occurs developmentally, in adulthood and in response to demyelination. PLoS ONE 12(7):e0180697","journal-title":"PLoS ONE"},{"issue":"9","key":"12785_CR43","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/sj.mp.4001379","volume":"8","author":"EM Hol","year":"2003","unstructured":"Hol EM, Roelofs RF, Moraal E, Sonnemans MA, Sluijs JA, Proper EA, de Graan PN, Fischer DF et al (2003) Neuronal expression of GFAP in patients with Alzheimer pathology and identification of novel GFAP splice forms. Mol Psychiatry 8(9):786\u2013796","journal-title":"Mol Psychiatry"},{"issue":"3","key":"12785_CR44","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.neurobiolaging.2013.09.035","volume":"35","author":"W Kamphuis","year":"2014","unstructured":"Kamphuis W, Middeldorp J, Kooijman L, Sluijs JA, Kooi EJ, Moeton M, Freriks M, Mizee MR et al (2014) Glial fibrillary acidic protein isoform expression in plaque related astrogliosis in Alzheimer\u2019s disease. Neurobiol Aging 35(3):492\u2013510","journal-title":"Neurobiol Aging"},{"issue":"14","key":"12785_CR45","doi-asserted-by":"crossref","first-page":"10527","DOI":"10.1074\/jbc.M109.067975","volume":"285","author":"G Tang","year":"2010","unstructured":"Tang G, Perng MD, Wilk S, Quinlan R, Goldman JE (2010) Oligomers of mutant glial fibrillary acidic protein (GFAP) Inhibit the proteasome system in alexander disease astrocytes, and the small heat shock protein alphaB-crystallin reverses the inhibition. J Biol Chem 285(14):10527\u201310537","journal-title":"J Biol Chem"},{"issue":"3","key":"12785_CR46","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.nbd.2005.05.021","volume":"20","author":"MA Korolainen","year":"2005","unstructured":"Korolainen MA, Auriola S, Nyman TA, Alafuzoff I, Pirttil\u00e4 T (2005) Proteomic analysis of glial fibrillary acidic protein in Alzheimer\u2019s disease and aging brain. Neurobiol Dis 20(3):858\u2013870","journal-title":"Neurobiol Dis"},{"key":"12785_CR47","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577744","volume":"361","author":"G Katsipis","year":"2021","unstructured":"Katsipis G, Tzekaki EE, Tsolaki M, Pantazaki AA (2021) Salivary GFAP as a potential biomarker for diagnosis of mild cognitive impairment and Alzheimer\u2019s disease and its correlation with neuroinflammation and apoptosis. J Neuroimmunol 361:577744","journal-title":"J Neuroimmunol"},{"issue":"6","key":"12785_CR48","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/alz.12447","volume":"18","author":"P Chatterjee","year":"2022","unstructured":"Chatterjee P, Pedrini S, Ashton NJ, Tegg M, Goozee K, Singh AK, Karikari TK, Simr\u00e9n J et al (2022) Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer\u2019s disease. Alzheimers Dement 18(6):1141\u20131154","journal-title":"Alzheimers Dement"},{"issue":"6","key":"12785_CR49","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/jnnp-2021-327788","volume":"93","author":"L Chouliaras","year":"2022","unstructured":"Chouliaras L, Thomas A, Malpetti M, Donaghy P, Kane J, Mak E, Savulich G, Prats-Sedano MA et al (2022) Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer\u2019s disease, frontotemporal dementia and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 93(6):651\u2013658","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12785_CR50","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.parkreldis.2022.02.023","volume":"97","author":"GM Parkin","year":"2022","unstructured":"Parkin GM, Corey-Bloom J, Long JD, Snell C, Smith H, Thomas EA (2022) Associations between prognostic index scores and plasma neurofilament light in Huntington\u2019s disease. Parkinsonism Relat Disord 97:25\u201328","journal-title":"Parkinsonism Relat Disord"},{"issue":"10","key":"12785_CR51","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1038\/s41380-023-02230-9","volume":"28","author":"E Lepinay","year":"2023","unstructured":"Lepinay E, Cicchetti F (2023) Tau: a biomarker of Huntington\u2019s disease. Mol Psychiatry 28(10):4070\u20134083","journal-title":"Mol Psychiatry"},{"issue":"1","key":"12785_CR52","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3233\/JHD-220557","volume":"12","author":"S Salem","year":"2023","unstructured":"Salem S, Cicchetti F (2023) Untangling the role of Tau in Huntington\u2019s disease pathology. J Huntingtons Dis 12(1):15\u201329","journal-title":"J Huntingtons Dis"},{"key":"12785_CR53","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.659898","volume":"13","author":"HS Gleerup","year":"2021","unstructured":"Gleerup HS, Sanna F, H\u00f8gh P, Simr\u00e9n J, Blennow K, Zetterberg H, Hasselbalch SG, Ashton NJ et al (2021) Saliva neurofilament light chain is not a diagnostic biomarker for neurodegeneration in a mixed memory clinic population. Front Aging Neurosci 13:659898","journal-title":"Front Aging Neurosci"},{"key":"12785_CR54","volume-title":"Biomarkers for Huntington's disease","author":"SW Granger","year":"2023","unstructured":"Granger SW, Thomas EA (2023) Exploration of saliva biomarkers for Huntington\u2019s disease. In: Thomas EA, Parkin GM (eds) Biomarkers for Huntington\u2019s disease. Springer, Switzerland"},{"key":"12785_CR55","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fnins.2020.00073","volume":"14","author":"J Corey-Bloom","year":"2020","unstructured":"Corey-Bloom J, Haque A, Aboufadel S, Snell C, Fischer RS, Granger SW, Granger DA, Thomas EA (2020) Uric acid as a potential peripheral biomarker for disease features in Huntington\u2019s patients. Front Neurosci 14:73","journal-title":"Front Neurosci"},{"issue":"1","key":"12785_CR56","doi-asserted-by":"crossref","first-page":"7371","DOI":"10.1038\/s41598-018-25095-3","volume":"8","author":"J Corey-Bloom","year":"2018","unstructured":"Corey-Bloom J, Haque AS, Park S, Nathan AS, Baker RW, Thomas EA (2018) Salivary levels of total huntingtin are elevated in Huntington\u2019s disease patients. Sci Rep 8(1):7371","journal-title":"Sci Rep"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12785-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12785-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12785-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T16:42:04Z","timestamp":1739637724000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12785-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["12785"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12785-4","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"25 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was approved by the University of California, San Diego (UCSD) Institutional Review Board, in accordance with the requirements of the Code of Federal Regulations on the Protection of Human Subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants provided their written informed consent to participate in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"158"}}